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MetalloproteinaseAbstract Objective: The speciﬁc causative mechanisms of abnormal luminar dilatation in coro-
nary artery ectasia (CAE) are essentially unknown. Destruction of the extracellular matrix may
be responsible for ectasia formation. Thus, we investigated the role of matrix metalloproteinases
(MMP9), and inﬂammatory marker (high-sensitive C-reactive protein) in CAE patients.
Methods: This study consisted of 30 consecutive CAE patients, 30 obstructive coronary artery dis-
ease (CAD) patients, and 20 controls with normal coronary arteries undergoing cardiac catheteri-
zation. Plasma levels of MMP-9, and hs-CRP were measured.
Results: Hs-CRP level was signiﬁcantly higher in the the CAE group than both in the CAD and
control groups (2.3 ± 0.5, 1.19 ± 0.54, 0.8 ± 0.3 mg/l, respectively, both p< 0.001), while,
MMP-9 level was signiﬁcantly higher in both CAE group and CAD than control groups
(27.71 ± 4.7, 25.2 ± 4.1, 18.6 ± 3.3 ng/ml, respectively , both p< 0.001). In subgroup analyses,
MMP-9 level was signiﬁcantly higher in CAE patients with multivessel involvement compared to
those with single-vessel ectasia (29.4 ± 3.1 vs. 25.2 ± 5.5 ng/ml, P= 0.01), while hs CRP level
was comparable in both groups (2.3 ± 0.52 vs. 2.4 ± 0.45 ng/ml, P= 0.82).
Conclusion: Our results suggest that the increased levels of MMP-9, hs-CRP may be responsible for
ectasia formation in patients with CAE and plasma level of MMP-9 is correlated with the severity of
CAE.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Coronary artery ectasia (CAE) was deﬁned as a dilation
exceeding 1.5-fold normal diameter in major coronary arter-
ies.1,2 It causes adverse coronary events like vasospasm, dissec-
tion, and thrombosis3 and was found in the range of 1.2–4.9%
in different series.3,4 Extensive structural damage was observed
in different layers of the vessel especially in the tunica media
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considered to be a different form of vascular remodeling in
response to atherosclerosis; however, the underlying mecha-
nisms responsible for ectasia formation are clearly unknown.
Earlier studies have reported that CAE is associated with
concomitant aneurysms in other vascular beds such as ascend-
ing thoracic aorta, abdominal aorta and its major branches
possibly because of a common underlying mechanism. These
studies have proved that development of aneurysm is associ-
ated with the destruction of extracellular matrix.6,7 A few stud-
ies investigating the proteolytic role of MMPs in CAE patients
are found.8–11 These studies have shown divergent results.
Similarly, studies evaluating the role of inﬂammatory mark-
ers including C-reactive protein (CRP) have also demonstrated
different results.9–13 Therefore, we aimed to investigate the role
of MMP-9 and inﬂammatory markers such as high-sensitive
CRP (hs-CRP) in patients with CAE and the relationship be-
tween these markers and the severity of CAE.
2. Patients and methods
Eighty patients with angina pectoris and objective evidence of
ischemic heart disease indicated by echocardiographic evidence
of regional wall motion abnormality, positive stress tests (stress
ECG, Exercise or pharmacological stress myocardial perfusion
imaging or positive dobutamine stress echocardiography) and
those with equivocal stress ECG and high pretest likelihood
for CAD who underwent coronary angiography were selected
and prospectively enrolled in the study. On the basis of their
angiographic ﬁndings, they were sorted into three groups:
 Group1: 30 patients with isolated CAE (CEA group),
 Group2: 30 patients with obstructive CAD (CAD group),
 Group3: 20 patients with angiographically normal coronary
arteries (Control group).
For more comparative analysis, CEA and CAD groups
were further divided into those with single vessel and multives-
sel involvement (Fig. 1). CAD and control groups were se-
lected on the basis of maximum available matching to the
CEA group regarding age, sex, risk factors and current medi-Figure 1 An example of a patient wcations to minimize confounding factors. Medical history, ath-
erosclerotic risk factors, and medications were interrogated in
case report forms. Blood samples were obtained at least 7 days
after coronary angiography to avoid the possible effect of angi-
ography on inﬂammatory situations.
Patients with acute coronary syndromes, known aortic
aneurysms, hematological disorders, acute/chronic infectious
diseases, hepatitis or previously known inﬂammatory/autoim-
mune disorders, acute/chronic renal failure, documented can-
cer, use of steroids, previous PCI or CABG, Combined
ectasia and obstructive CAD were excluded from the study.
All patients were provided informed consent for participa-
tion in this study.
3. Assay of proteolytic and inﬂammatory markers
Blood samples were drawn into tubes including EDTA after an
8-h fasting period in the morning with minimal trauma from
antecubital vein. Plasma was separated by centrifugation at
3000 g for 10 min and then stored at 20 C.
According to the manufacturer’s instructions, plasma levels
of MMP-9 were assayed by a speciﬁc two-site enzyme linked
immunosorbent assay (ELISA) sandwich method using their
speciﬁc trade kits (Biotrak MMP-9 human ELISA systems,
Amersham Pharmacia Biotech, Buckinghamshire, UK). Plas-
ma hs-CRP level was measured according to the manufac-
turer’s instructions (Dade Behring Inc., Marburg, Germany).
4. Angiographic evaluation
Coronary angiography was performed using standard tech-
nique. Images were recorded in digital format and stored for
later analyses using Toshiba inﬁnity model DFP-8000D cathe-
terization machine.
Evaluations were visually performed by two experienced
angiographers blinded to the patient’s biochemical data. The
vessel diameter was calculated quantitatively in case of the
presence of conﬂict about CAE.
Coronary ectasia was deﬁned as a dilation exceeding the
1.5-fold normal diameter in major coronary arteries.1,2 A lumi-
nal narrowing greater than 50% in the coronary artery wasith multivessel coronary ectasia.
Matrix metalloproteinase-9 (MMP9) and high sensitivity C – Reactive protein (hs-CRP) in coronary artery ectasia 291considered obstructive CAD. Absence of any atherosclerotic
plaques was regarded as normal coronary artery.
4.1. Statistical analysis
Numerical data were presented as mean ± SD. They were
compared using Student’s t-test, Mann–Whitney U test and/
or ANOVA/post hoc tests when appropriate. Categorical data
were presented as frequencies (%). Association between differ-
ent categorical variables were done using chi square test (X2).
Receiver operating characteristic (ROC) curves were in-
structed with Area under the curves (AUC) for MMP9 and
hs-CRP alone and for them combined were compared. Sensi-
tivity, speciﬁcity, PVP, NPV and accuracy together with Odds
ratio (OR) were calculated at chosen cut-off values. P values
60.05 were considered statistically signiﬁcant. All statistical
tests were run on SPSS for windows, release 17.0 (SPSS Inc.,
Chicago, Ill, USA) 14.
5. Results
5.1. Patient characteristics, risk factors and medications
All the three groups were age, sex, risk factors and medications
matched as shown in Table 1.
5.2. Hs-CRP and MMP-9 in study population
Hs-CRP level was signiﬁcantly higher in the CAE group
(2.3 ± 0.5 mg/l) than both in the CAD (1.19 ± 0.54 mg/l,
p< 0.001), and the control groups (0.8 ± 0.3 mg/l,
p< 0.001), while MMP-9 level was signiﬁcantly higher in both
the CAE group (27.71 ± 4.7 ng/ml) and CAD (25.2 ± 4.1 ng/
ml) than the control groups (18.6 ± 3.3 ng/ml, p< 0.001).
5.3. Hs-CRP and MMP-9 in study subgroups
Subgroup analysis showed that 12 patients in the CAE group
had single vessel ectasia and 18 patients had multivessel ectasia
while in the obstructive CAD group 11 patients had single ves-
sel disease and 19 patients had multivessel disease. In subgroup
analyses within the CAE group, MMP-9 level was signiﬁcantly
higher in CAE patients with multivessel involvement com-
pared with those with single-vessel ectasia (29.4 ± 3.1 vs.
25.2 ± 5.5 ng/ml, P= 0.01) signifying the relation of MMP-Table 1 Patient characteristics, risk factors and medications.
Variables CAE group (n= 30) CAD group
Age 50.7 ± 6.4 53.5 ± 6.7
Male/female 27/3 26/4
Diabetes 8 (26.7%) 11 (36.7%)
Hypertension 9 (30%) 12 (40%)
Smoking 24 (80%) 25 (83.3%)
B-Blockers 26(96%) 26 (96%)
Aspirin 29 (96.7%) 30 (100%)
Nitrates 9 (32%) 12 (44%)
Statins 8 (28%) 11 (41%)9 to the severity of CAE, while, hs-CRP level was comparable
in both groups (2.3 ± 0.52 vs. 2.4 ± 0.45 ng/ml, P= 0.82).
In addition, MMP-9 and hs-CRP levels were signiﬁcantly
higher in CAE with single vessel involvement compared to
CAD with single vessel involvement (25.1 ± 5.5 vs. 21 ±
2.1 ng/ml, P= 0.03) and (2.36 ± 0.45 vs. 1.1 ± 0.47 mg/l,
P< 0.001), respectively.
Also, hs-CRP level was signiﬁcantly higher in CAE with
multivessel involvement compared with CAD with multivessel
involvement (2.3 ± 0.52 vs. 1.2 ± 0.59 mg/l, P< 0.001),
while MMP-9 was comparable in both groups (29.4 ± 3.1
vs. 27.57 ± 2.8 ng/ml, P= 0.06).
Receiver operating characteristic (ROC) curve analysis
(Fig. 2), showed hs-CRP levels greater than or equal to
1.3 mg/l identiﬁed CAE patients with 96.7% sensitivity and
80% speciﬁcity(area under curve = 0.96, P< 0.001). also,
MMP-9 levels greater than or equal to 25 ng/ml identiﬁed
CAE patients with 73.3% sensitivity and 70% speciﬁcity (area
under curve = 0.78, P= 0.001).
Chi –square test showed a strong association between CAE
and high MMP9 level 22/30 (73.3%) vs. b35/50 (70%) with an
estimated risk of (6.4 times) more than patients with normal
MMP9 (OR= 6.4, 95% CI = 2.33–17.6).
Similarly, there is a strong association between CAE and
high hs CRP level 29/30(96.7%) vs. 40/50(80%) with an esti-
mated risk of 116 times more than patients with normal hs-
CRP (OR= 116, 95% CI = 14.1–957.3).
6. Discussion
Histopathological characteristics of CAE are similar to those of
coronary atherosclerosis, which most likely points out a com-
mon shared mechanism between CAE and atherosclerosis.4
The accumulation of inﬂammatory cells and damage of the
extracellular matrix, elastin and collagen ﬁbrils have been dem-
onstrated in ectatic arteries.4,5 The severity of these changesmay
be related to the diameter of ectatic vessels.5 In contrast, it is un-
known why the atherosclerotic process rarely leads to abnormal
vessel dilatation while it most frequently results in obstructive
CAD during the progression of atherosclerosis. A limited num-
ber of studies have evaluated the role of inﬂammatory (CRP and
IL-6) and proteolytic markers (MMPs, TIMPs) in the CAE pa-
tients.8–13 They provided divergent results.
In our study, we found signiﬁcantly higher levels of hs-CRP
in CAE when compared to CAD and controls. Also in sub-
group analysis, hs-CRP was signiﬁcantly higher in the single
vessel ectasia group than in the single vessel obstructive(n= 30) Control group (n= 20) P-value
48.3 ± 8.2 NS
17/3 NS
6 (30%) NS
5 (25%) NS
12 (60%) NS
18 (82%) NS
19 (95%) NS
8 (36%) NS
8 (36%) NS
Figure 2 ROC curves for MMP9 and hs-CRP in CAE.
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pared with those CAD with multivessel involvement. These
ﬁndings highlight the importance of the inﬂammatory process
in the pathogenesis of CAE.
These ﬁndings were concordant with Turhan et al.13 ﬁnd-
ings in which 32 patients with isolated CAE compared to 32
patients with obstructive CAD showed signiﬁcantly higher
hs-CRP levels in patients with CAE.
Whereas, Finkelstein et al.10 found no signiﬁcant difference
in hs-CRP levels in CAE compared to CAD. This conﬂicting
result may be due to confounding factors and patient’s heter-
ogeneity including the use of statins or ACE inhibitors at the
beginning of the study and these agents might suppress the
inﬂammatory process. We avoided these confounding factors
by having age, sex and risk factors matched groups.
The matrix metalloproteinases (MMPs) are a large family
of zinc dependent, extracellularly acting endopeptidases, the
substrates of which are proteins of the extracellular matrix
and adhesion proteins. Matrix metalloproteinase-9 (MMP9),
is also known as gelatinase B, 92 kDa gelatinase, or 92 Da type
IV collagenase.15 The matrix metalloproteinase family of en-
zymes is involved in arterial wall extracellular matrix degrada-
tion and remodeling. The latter activities have been implicated
in a number of normal and pathologic processes, such as ath-
erosclerotic lesion formation and progression, plaque destabi-
lization and rupture, and also in plaque stabilization and
healing.16 Konstantino et al.17 pointed out the prominent role
of MMP9 in plaque formation, destabilization, and rupture,
and postulated that MMP9 levels may serve as a biomarker
for acute coronary syndrome. An association of MMP9 levels
with atherosclerotic changes has been previously found in pa-
tients with atherosclerosis of the femoral artery.18 In a large
prospective study of middle-aged men (465 cases, 1076 con-
trols), Welsh et al.19 showed an association of serum MMP9
with the incidence of coronary heart disease in the general
population.The human MMP9 gene was mapped to the chromosome
region 20q11.2–q13.115 and several polymorphisms of this
gene were identiﬁed. Plasma levels of MMP-9 were signiﬁ-
cantly higher in CAE and CAD patients than in controls.
However it was statistically insigniﬁcant in CAE compared
to CAD (P= 0.06). It is worth noting that within the CAE
group, MMP-9 level was signiﬁcantly higher in CAE patients
with multivessel ectasia compared to those with single-vessel
ectasia. This ﬁnding suggests a correlation of MMP-9 level
with extent and severity of CAE. Moreover, MMP-9 level
was signiﬁcantly higher in CAE with single vessel involvement
compared with those CAD with single vessel involvement.
Destruction of extracellular matrix by MMPs may weaken
the connective tissue in the vessel wall, thereby leading to thin-
ning and dilatation of the vascular wall.20–22 MMP-9 digests
gelatin and several types of collagens.11 The activity of MMPs
is regulated predominantly by TIMP-1. TIMPs are inactivated
by both MMPs and different ILs.23
Our ﬁndings agree and conﬁrmed the results of Dogan
et al’s.24 study in which they examined MMP-3, MMP-9,
and TIMP-1in 28 consecutive CAE patients, 27 obstructive
CAD patients, and 22 controls with normal coronary arteries.
MMP-9 levels were signiﬁcantly higher in CAE compared with
CAD and control groups suggesting that more severe inﬂam-
mation may be involved in the pathogenesis of CAE.
Finally, while most experimental and clinical trials of MMP
inhibitors have not demonstrated signiﬁcant beneﬁts, some tri-
als still showed promising results. With the advent of new ge-
netic and pharmacological tools, disease-speciﬁc MMP
inhibitors with fewer undesirable effects are being developed
and could be useful in the management of vascular disease.25
7. Limitations
The population of our study was rather small to provide a def-
inite conclusion, in particular subgroups’ size. Destruction of
the extracellular matrix in the cardiovascular system involves
enzymes other than the MMP family, such as catepsins and
cystatins. These catabolic enzymes were not assessed in our
study.
8. Conclusions
Our results suggest that the increased level of MMP-9 and hs-
CRP may be responsible for ectasia formation in patients with
CAE, and plasma level ofMMP-9 is correlated with the severity
of CAE, These ﬁndings provide further evidence for the role of
proteolytic and inﬂammatory activities in ectasia formation.
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